Immunization against self-tumor antigens can induce T-regulatory cells, which inhibit proliferation of type I CD4 þ T-helper (T H 1) and CD8 þ cytotoxic T cells. Type I T cells are required for potent antitumor immunity. We questioned whether immunosuppressive epitopes could be identified and deleted from a cancer vaccine targeting insulin-like growth factor-binding protein (IGFBP-2) and enhance vaccine efficacy. Screening breast cancer patient lymphocytes with IFN-g and interleukin (IL)-10 ELISPOT, we found epitopes in the N-terminus of IGFBP-2 that elicited predominantly T H 1 whereas the C-terminus stimulated T H 2 and mixed T H 1/T H 2 responses. Epitopespecific T H 2 demonstrated a higher functional avidity for antigen than epitopes, which induced IFN-g (P ¼ 0.014).
Introduction
Cancer vaccines have progressed slowly from clinical testing into standard-of-care use despite decades of development and evaluation. The majority of vaccines that have advanced to later stage clinical trials have been protein-or tumor cellbased. Both vaccine platforms supply intact antigen for presentation to the immune system. In general, phase III studies reported with these types of vaccines have shown little or modest clinical efficacy in definitive randomized trials (1) (2) (3) . Obstacles to improved efficacy have included the poor immunogenicity of self-proteins, which are cancer-associated antigens, low-to-moderate immune responses elicited by vaccination, and the observation that active immunization against self-antigens can induce immunosuppressive cells, such as Tregulatory cells (Treg), to proliferate (4) .
In the last several years, there has been an increased understanding of the type of immune response that is needed to elicit tumor destructive immunity. Patients with cancer who endogenously develop type I T cells (both IFN-g-secreting CD4
þ and activated cytotoxic T cells) capable of infiltrating their tumors have a significantly improved disease outcome as compared with individuals who do not mount such an immune response (5, 6) . Recent studies of a variety of cancer vaccines have reported a correlation of vaccine-induced type I T-cell levels, specifically T-helper (T H ) 1 cells, with disease resolution or overall survival benefit after immunization (7) (8) (9) . For cancer vaccines, the main mode of stimulating the development and activation of T H 1 cells has been vaccine adjuvants to induce the appropriate co-stimulatory signals or alter the cytokine milieu of the vaccine environment to elicit T H 1 (10, 11) . There has been little exploration of the modulation of the antigenic epitope within the T-cell receptor (TCR; ref. 12) . Investigations have well-documented that the nature of the T H epitope presented to the TCR is the first signal in the differentiation of a na€ ve T H cell into a specific T H phenotype (13) . As T H 1 cytokines have been shown to be much more effective than T H 2 cytokines in activating antigen-presenting cells (APC) to stimulate tumor-specific adaptive immunity and T H 2 have been shown to suppress T H 1 cells, it would be a benefit to develop a vaccine that included only antigenic amino acid sequences that elicited primarily or exclusively T H 1 responses (14, 15) .
We questioned whether screening epitopes derived from a self-tumor antigen for sequences that may induce antigenspecific Treg or T H 2 and then eliminating those epitopes from a subunit vaccine would enhance vaccine efficacy. Studies described below demonstrate that specific peptides of selfproteins can preferentially elicit IFN-g or interleukin (IL)-10 secretion by T cells. Elimination of epitopes that elicit IL-10 secretion assures the antitumor potency of an insulin-like growth factor-binding protein (IGFBP-2)-directed vaccine.
Materials and Methods
Evaluation of antigen-specific T-cell phenotype and functional avidity IGFBP-2 peptides, predicted to bind promiscuously to human MHCII, were selected using web-based algorithms as previously described (16) . Peripheral blood mononuclear cells (PBMC) from 20 female patients with breast cancer, obtained by a University of Washington Institutional Review Boardapproved informed consent, were cryopreserved and evaluated by ELISPOT for antigen-specific IFN-g or IL-10 secretion, according to our published methods (17, 18) . Data are reported as the mean number of spots for each experimental antigen minus the mean number of spots detected in no-antigen control wells (corrected spots per well, CSPW). Positive responses were defined by a statistically significant difference (P < 0.05) between the mean number of spots from 5 replicates in the experimental wells and the mean number from noantigen control wells for an individual.
Some donors, who demonstrated either an IFN-g restricted (n ¼ 5) or IL-10-restricted epitope-specific response (n ¼ 4), had their PBMCs assessed for the appropriate cytokine secretion induced by a single epitope at varying concentrations (10, 1, 0.1, and 0.01 mg/mL; ref. 18) . For each donor, data are graphed as best-fit nonlinear regression curves for the mean CSPW generated at all peptide concentrations. The mean half-maximal effective peptide concentration (EC 50 ) is calculated for each curve using the "log(agonist) versus response -Find ECanything" analysis in GraphPad Prism.
Antigen-specific IFN-g production by mouse spleen cells was quantitated by ELISPOT as we have reported (18) , with the modification that polyvinylidene difluoride (PVDF) plates (Millipore) were coated with 10 mg/mL anti-mouse IFN-g (clone AN-18; Mabtech) and 5 mg/mL biotinylated anti-mouse IFN-g (clone R4-6A2; Mabtech). Data are reported as CSPW as defined above.
Generation of human and murine IGFBP-2-specific T H 1 and T H 2 cell lines
Human antigen-specific T-cell lines were generated for phenotyping using our published methods (18) . Spleen cells from IGFBP-2 (1-163) (N-terminus)-vaccinated mice were stimulated with a pool of peptides; p8-22, p17-31, p67-81, p99-113, p109-123, and p121-135 (10 mg/mL each) and IGFBP-2 (164-328) (C-terminus)-vaccinated mice were stimulated with p164-178, p190-204, p213-227, p235-249, p251-265, p266-280, p291-305, p307-321 (10 mg/mL each) peptides. The T cells were subjected to a second in vitro stimulation on day 8 by adding equivalent numbers of peptide-loaded (10 mg/mL) autologous-irradiated (3,000 rads) splenic cells to the original culture. A total of 10 ng/mL recombinant mouse IL-7 (R&D Systems), 5 ng/mL recombinant human IL-15 (PreproTech, Inc.), and 10 U/mL recombinant human IL-2 (Hoffman-LaRoche) were added on days 5 and 12, with additional IL-2 on days 15 and 18 for T-cell expansion (16) .
Assessment of T-cell phenotype
Antibodies were obtained from eBioscience (murine) or Biolegend (human). Receptor expression was documented in the expanded T cells by adding phycoerythrin (PE)-Cy7-conjugated anti-mouse CD49b (clone: DX5; 0.5 mg), allophycocyanin (APC)-conjugated anti-mouse CD4 (clone: GK1.5; 0.2 mg), or APC-conjugated anti-human CD4 (clone: OKT4; 20 mL), PerCPconjugated anti-mouse CD3 (clone: 145-2C11; 0.2 mg), or PECy7-conjugated anti-human CD3 (clone: UCHT1; 20 mL) and fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD19 (clone: 1D3; 0.5 mg). For extracellular staining, cells were incubated 30 minutes with the receptor antibodies. Intracellular expression of FOXP3 was documented after permeablization and fixation with the FOXP3 Buffer Set (Biolegend) according to the manufacturer's instructions and staining with PE-conjugated anti-mouse FOXP3 (clone: 150D/E4; 0.5 mg) and anti-mouse CD4 or PE-conjugated anti-human FOXP3 (clone: 206D; 20 mL) and anti-human CD4. Flow cytometry was performed on the FACSCanto (BD Biosciences) and data analyzed using FlowJo software (BD Biosciences). Typically, 100,000 cells were collected per sample. Results are reported as a percentage of total cell number or a percentage of a specific cell population.
Cytokine levels in the murine T-cell cultures were assessed according to manufacturer's instructions using the appropriate ELISA (eBioscience) on medium collected from the splenic T cell lines on day 10 of culture. Data are expressed as mean ng/mL AE SD of 3 separate expansions.
Vaccine construction
IGFBP-2 (1-163) (N-terminus) and IGFBP-2 (164-328) (Cterminus) were amplified using the primers and conditions listed in Supplementary Table S1 with the Herculase II polymerase (Stratagene). For the IGFBP-2 (1-328) (full-length) construct, cDNA was made from RNA extracted from the human breast cancer cell line, MCF-7 [American Type Culture Collection (ATCC)]. The cDNA was amplified using primers and conditions listed in Supplementary Table S1 . The insert and eukaryotic expression vector, pUMVC3 (National Gene Vector Biorepository), were cut with EcoRI and BamHI restriction enzymes and ligated using Escherichia coli ligase (New England Biolabs). Transformation of XL1 blue competent bacteria (Stratagene) allowed kanamycin-resistant clone selection. Sequencing (Agencourt/Beckman Coulter Genomics) was performed on each clone and each large-scale DNA prep (Qiagen) to confirm identity. All DNA plasmids were determined to express the correct-sized protein in vitro by transfecting HEK-293 (ATCC) cells using Polyfect reagent (Qiagen) and Western blotting probing with anti-IGFBP-2 polyclonal antibodies (Santa Cruz Biotechnology, Inc.; data not shown).
Sequence alignment
N-terminal (amino acids 1-163) or C-terminal IGFBP-2 (amino acids 164-328) sequences were aligned with human, viral, bacterial, or fungal proteins searching the ref seq_protein database in NCBI's DELTA-BLAST algorithm using the default parameters. Alignments with less than 35% positivity (identical amino acids or conservative amino acid substitutions) more than 80 amino acids were excluded as insignificant homology (19) . Thirty-five percent represents a conservative assessment for identification of potential cross-reactive sequences for allergens (19) . Data are reported as the percentage positivity (number of positive amino acids/total amino acids examined Â 100).
Vaccination, adoptive transfer, and assessment of tumor growth
Animal care and use were in accordance with institutional guidelines. Female FVB/N-TgN (MMTVneu)-202Mul mice (TgMMTVneu) (6-8 weeks old; mean weight, 18.5 g; range, 15.4-23.1 g; Jackson Laboratory) were immunized with IGFBP-2 DNA constructs or pUMVC3 vector alone (50 mg plasmid) as a mixture in complete Freund's adjuvant/incomplete Freund's adjuvant (Sigma). Three immunizations were given 2 weeks apart. For tumor challenge, a syngeneic mouse mammary tumor cell line, MMC (0.5 Â 10 6 cells), was implanted into the mammary fat pad 2 weeks after the last vaccine or 7 days before T-cell adoptive transfer (n ¼ 10/group; ref. 20) . Tumors were measured as previously described (16) . Briefly, measurements on length, width, and depth were assessed by Vernier caliper 2 to 3 times per week by the same technician at each time point. The measurements were multiplied by the volume constant of an ellipsoid shape, or p/6, to calculate tumor volumes. All tumor growth is presented as mean tumor volume (mm 3 AE SEM). Data are representative of two independent experiments.
For adoptive transfer, 5 Â 10 6 IGFBP-2 N-terminal-or Cterminal-specific T cells were transferred into tumor-bearing mice by i.v. tail vein injection. The same number of splenocytes derived from na€ ve mice were used as a control infusion. Data are representative of two independent experiments.
In vivo T-cell depletion
Depletions were performed as previously described (21) . Briefly, mice were vaccinated with the N-terminus vaccine 3 times, 14 days apart as described above. MMC cells were implanted 2 weeks from the last vaccine. Monoclonal antibodies were used for in vivo depletion (250 mg of anti-CD4; clone GK1.5 and 100 mg of anti-CD8; clone 2.43, UCSF Monoclonal Antibody Core) via intraperitoneal injection of the specific antibody three consecutive days before MMC implant and twice per week until the experiment was terminated. Rat IgG2b was used as a control. Data are shown as the mean AE SEM of 5 mice per group.
Statistical analysis
The unpaired, 2-tailed Student t test, Fischer exact test, or c 2 test was used to evaluate differences between groups. P < 0.05 was considered significant. In vivo studies were designed on the basis of a priori power calculations generated by in vivo modeling of previous experiments with the same dose of MMC (Sample Size Predictor, Stata I2.0 IC). When control tumors reached a size that achieved 80% power with a significance level of 0.05 using a 2-sided, 2-sample test to reject the null hypothesis (Stata IC), the experiments were terminated. All statistical analyses were performed using GraphPad Prism 5.04 (GraphPad Software).
Results
The IGFBP-2 C-terminus is enriched for epitopes that induce IL-10-secreting T cells as compared with the N-terminus Investigations indicate the predominant cellular immune response in most patients with breast cancer is of a T H 2 phenotype (22, 23) . As epitope motifs have been shown to influence T H phenotype, we questioned whether we could identify sequences within a self-antigen that were specific for eliciting T H 1 versus T H 2 or Treg for the purpose of excluding immune suppressive sequences from an epitope-based vaccine construct (13) . We chose to analyze T H 2/Treg by examining IL-10 secretion, as IL-10 has been shown to negatively regulate T H 1 activity and enhance the expression of TGF-b, mediating the conversion of T H 1 to T H 2 (24, 25) . Furthermore, IL-10 is also secreted by Tregs, which can proliferate via self-peptide stimulation (26) . IGFBP-2 epitope-induced IL-10 and IFN-g secretion was variable in breast cancer PBMCs (Fig. 1A) . We noted that epitopes within the C-terminus (p190-p307) of the protein were more immunogenic, stimulating a greater magnitude IL-10 and IFN-g response than epitopes in the Nterminus. The mean IL-10 epitope-specific response (18 CSPW; range, 0-129 CSPW) in the C-terminus was 6-fold greater than the mean IL-10 epitope-specific response in the N-terminus (3 CSPW; range, 0-44 CSPW; P < 0.001). The mean IFN-g epitope-specific response (12 CSPW; range, 0-82 CSPW) in the C-terminus was 2-fold greater than the mean IFN-g epitope-specific response in the N-terminus (6 CSPW; range, 0-70 CSPW; P ¼ 0.022). Epitopes in the C-terminus equally elicited the same magnitude of IFN-g and IL-10-secreting cells by ELISPOT (P ¼ 0.132). In contrast, epitopes derived from the N-terminus of IGFBP-2 induced 3-fold more IFN-g-secreting cells than IL-10-secreting cells by ELISPOT (P ¼ 0.012). Figure 1B shows the percentage of patients with a specific response to individual epitopes. In some patients, individual epitopes were shown to induce exclusively IFN-g or IL-10-secreting cells by ELISPOT. In some patients, individual epitopes induced a mixed response with evidence of both IFN-g and IL-10-secreting cells. When responses were pooled and grouped by N-and C-terminus rather than by individual epitopes, a significantly greater number of patients responded to the C-terminus of the protein (mean responder, 42%), compared with the N-terminus (mean responder, 31%; P ¼ 0.007). The C-terminal epitopes induced a mix of both IL-10 and IFN-g secretion in response to antigen in a higher percentage of patients (mean responder, 20%) than that induced by the Nterminal epitopes (mean responder, 7%; P ¼ 0.003) where responses appeared to be more restricted to either T H 1 or T H 2.
To assess whether the T cells elicited were T H 2 or FOXP3 IGFBP-2 epitope-specific T H 2 demonstrates a higher functional avidity and homology to a greater number of bacterial and self-proteins than IGFBP-2 epitopespecific T H 1 Titration studies documented that the peptides that induced IL-10 secretion were recognized by T cells with a higher functional avidity (mean EC 50 concentration, 0.11 AE 0.04 mg/mL; Fig. 2A ) than those peptides that induced an IFN-g response (mean EC 50 concentration, 2.4 AE 0.56 mg/mL; P ¼ 0.014; Fig. 2B ).
Our previous studies, which identified IGFBP-2 as a human antigen, had demonstrated that some epitopes derived from murine IGFBP-2 shared a high degree of homology with bacterial proteins (16) . Indeed, T cells specific for IGFBP-2 sequences were demonstrated as cross-reactive with highly homologous sequences from antigens such as Candia albicans and Pseudomonas aeruginosa (16) . We questioned whether this homology was associated with the T H 2 induction observed with the use of the C-terminus vaccine. The N-and C-terminus differed in the amount of sequence homologies shared with foreign antigens. We identified 157 bacterial species that demonstrated 35% shared amino acid positivity over 80 or more amino acids (range, 35%-43%) for the human IGFBP-2 C-terminus ( Fig. 2C; Supplementary Table S2 ). In contrast, the N-terminus demonstrated no sequence homology with bacterial proteins, a difference of more than 100-fold. There was no difference in the number of viral homologies between the 2 termini (N-term, 0 and C-term, 0).
The IGFBP-2 N-terminus shared significant homology with other IGFBP proteins, and only one additional self-protein, CYR61 ( Fig. 2C; Supplementary Table S3 ). The C-terminus also demonstrated significant homology with other IGFBP proteins but also to 9 additional self-proteins, including thyroglobulin, nidogens, and testicans ( Fig. 2C; Supplementary Table S4 ). Only 16% of all homologous sequences for the N-terminus were non-IGFBP-related whereas 64% of homologous sequences for the C-terminus were self-proteins other than IGFBP family members.
An N-terminus, but not IGFBP-2 C-terminus, vaccine both stimulates type I immunity and inhibits tumor growth
Human and murine IGFBP-2 are highly homologous (82%) and tumors that arise in the TgMMTV-neu overexpress IGFBP-2 (21). We immunized mice with DNA constructs encoding the N-terminus (1-163), the C-terminus (164-328), and the full length (1-328) of IGFBP-2. The N-terminus vaccine could elicit peptide-specific T H 1 (mean, 73 CSPW; range, 0-190 CSPW) compared with the C-terminus vaccine (mean, 10 CSPW; range, 0-89 CSPW; P ¼ 0.023) or the IGFBP-2 full-length sequence (mean, 0 CSPW; P ¼ 0.007; Fig. 3A) . The mean tumor volume of N-terminus-vaccinated mice (104.2 AE 8.4 mm 3 ) was significantly less than that observed in the empty vector control ) vaccinated mice (P < 0.001 for all; Fig. 3B ). Indeed, tumor growth after vaccination with the C-terminus and full-length constructs was no different than control (P > 0.15 for all). We also found that hIGFBP-2 (1-163) tumor volumes were significantly smaller than the vector control group, as determined by a 2-way ANOVA with repeated measures with a Bonferroni posttest, at multiple time points. Significance was observed as early as 22 days after tumor implant (P < 0.001) and additionally at 26 and 28 days after tumor implant (P < 0.0001).
Tumor inhibition was mediated by CD4 þ T cells (Fig. 3C) .
Elimination of CD8 þ T cells had no impact on the antitumor response elicited by vaccination with isotype control (P ¼
0.291). Depletion of CD4 þ T cells within 2 weeks of completing
immunizations, however, resulted in a significant loss of the tumor-inhibitory effect of the N-terminus vaccine (P ¼ 0.027) compared with vaccine without depletion and was no different than the administration of empty vector alone (P ¼ 0.291).
IGFBP-2 vaccine-induced T H 2 can abrogate the antitumor effect of IGFBP-2-specific T H 1
To confirm that the inability of the C-terminus vaccine to inhibit tumor growth was not due to the lack of an immune response, we evaluated cytokine secretion from T cell lines generated after vaccination. T cell lines derived from mice vaccinated with the N-terminus (mean, 77% CD3 þ cells) were divided equally between CD4 þ (mean, 50%) and CD8 þ (mean, 
Discussion
The generation of tumor-specific T H 1, via vaccination, can result in the activation of both innate immune cells and CD8 þ cytotoxic T cells (CTL). Vaccine-stimulated antigen-specific T H 1 secrete type I cytokines, such as IFN-g, which enhance the function of local antigen-presenting cells and augment endogenous antigen presentation (27) . An increased processing of tumor cells by the antigen-presenting cells results in epitope spreading, which is associated with tissue destruction. Many current cancer vaccine approaches, especially those that employ the use of whole intact antigen, elicit T H 2 or mixed T H 1/T H 2 immunity (28). Subunit or epitope-based vaccines may be much more effective for preferentially inducing T H 1 than whole antigen approaches. Data presented here demonstrate that a self-tumor antigen contains sequences that are capable of specifically stimulating either a T H 1 or T H 2 response. Moreover, the T H 2 generated by such epitopes are of a higher functional avidity than the T H 1 cells elicited, thus may compete more effectively for antigen/MHC complexes at the site of the tumor. Removal of T H 2-inducing sequences from a vaccine construct, however, will allow T H 1 dominance and an effective antitumor response.
The differentiation of a na€ ve T H cell into one with a mature phenotype is influenced by the binding of a particular peptide to the MHC (signal 1), the co-stimulation provided at the time of antigen recognition (signal 2), and the cytokine environment in which the immune response is generated (signal 3; ref. this agent has been shown to stimulate both T H 1 and T H 2 responses, thus would be less likely to bias to a specific T H phenotype (30) . We sought to influence signal 1 by determining whether immunosuppressive epitopes could be identified within a tumor antigen protein sequence and then removed. There have been several reports of tumor antigen-specific Tregs present in the peripheral blood of patients with cancer and volunteer donors. Two recent studies identified both mammoglobin-specific (31) and p53-specific Treg (32) in the blood of patients with breast cancer and volunteers, respectively. The Treg in both these models had common characteristics; they recognized specific class II binding peptide sequences and suppressed the response of conventional T cells and CTL. Presumably, p53 Treg in volunteer donor blood represents one mechanism of peripheral tolerance. (15) . Similar to NY-ESO Treg, we also found IGFBP-2 sequences that stimulated both IFN-g and IL-10. However, it was possible to identify sequences that elicited predominantly IFN-g secretion in response to antigen, allowing epitopes that generated mixed responses to be removed from the vaccine construct. The IGFBP-2 N-and C-termini differed significantly in the prevalence of T H 1-versus T H 2-inducing epitopes. We had previously reported that individual epitopes of IGFBP-2 shared significant sequence homology with foreign proteins, in particular bacterial antigens (16) . As the primary T H response to bacteria is T H 2, with type II cytokine secretion driving the development of antibodies needed to bind to and clear bacteria, we questioned whether the C-terminus may contain greater areas of homology with bacteria than the N-terminus. We used a standard methodology for predicting the potential for cross-reactivity to allergens, which requires a minimum of 35% identity over 80 amino acid sequences to define risk for cross-interaction (19, 33) . The IGFBP-2 C-terminus harbored more than 100-fold greater sequences with potential crossreactivity to bacterial antigens than the N-terminus. Potentially, the sequence similarity of the C-terminus to bacteria could be steering T H differentiation to type II. We also identified that the C-terminus had a greater sequence homology with numerous self-proteins outside of the insulin like growth factor receptor family, in contrast to the N-terminus whose homology was restricted. It has recently been reported that memory Tregs differentiate into T H 2 after downregulation of FOXP3 following in vitro expansion (34) . The C-terminus T H 2 could represent a pool of higher avidity T cells that have been stimulated by numerous self-antigens presented endogenously in the periphery and may play a role in maintaining selftolerance. IGFBP-2 T H 2 demonstrated a higher functional avidity than T H 1 responding to antigen at lower concentrations. In all likelihood, tumor antigen is presented in the context of MHC in low concentrations in the tumor bed. Subsequently, vaccineinduced T H 2 will more effectively compete for those peptide/ MHC complexes than lower avidity T H 1. Type II cytokines secreted in response to antigen stimulation will prevent APC activation and the development of CTLs. Removing the T H 2 dominant sequences and allowing a T H 1 dominant response resulted in inhibition of tumor growth after administration of an IGFBP-2 vaccine. In humans, although of a lower avidity, the T H 1 population boosted with active immunization may still be quite functional. Recent evidence suggests that CD4 þ T cells with lower functional avidity produce cytokines for longer periods of time and are less prone to experiencing exhaustion in the face of chronic antigen exposure (35) . In contrast, higher avidity T cells have been shown to be more likely to experience antigen-induced cell death, which could be a particular problem in situations of chronic antigen stimulation such as with cancer (36) . Furthermore, higher avidity T cells can become tolerized in the tumor microenvironment (37) . Clinical studies of cancer vaccines often use constructs encoding the full-length self-protein or immunize with the complete antigenic self-protein in adjuvant and rarely monitor both the T H 1 and T H 2 immune response generated with active immunization. Studies described here raise the question as to whether the lack of efficacy seen with many cancer vaccines might lie in the augmentation of T H 2 concurrent with T H 1. Selection of particular portions of a tumor antigen that specifically stimulate type I, but not type II, T cells provides the capability of developing vaccines that preferentially elicit T H 1 and CTL. Combination of a T H 1-generating cancer vaccine with potent adjuvants and/or checkpoint-blocking agents can have the potential to drive the type I immune response to therapeutic levels in vivo.
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